Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Chugai Pharmaceutical Publishes Transcript of FY2026 Q3 Financial Results Conference

By Public Technologies
  • Chugai Pharmaceutical’s October 27, 2026, FY2026 third-quarter results conference featured CEO Osamu Okuda and CFO Iwaaki Taniguchi.
  • Nine-month revenue reached JPY 1.07 trillion; core operating profit totaled JPY 536.1 billion.
  • Management expects to exceed its full-year forecast, with Actemra sales projected to beat expectations by more than JPY 10 billion.
  • ERP-related shipment front-loading boosted domestic sales by the low JPY 30 billion range; the one-time benefit will reverse in the fourth quarter.
  • Hemlibra’s autoinjector launch is targeted for Japan and global markets in 2027, with no material increase in the cost ratio expected.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.